Polaryx Therapeutics (PLYX) Prepaid Assets (2024 - 2026)

Polaryx Therapeutics (PLYX) posted quarterly Prepaid Assets of $389000.0 for Q1 2026, up 1340.74% quarter-over-quarter from $27000.0 in Q4 2025.

Polaryx Therapeutics (PLYX) Prepaid Assets (2024 - 2026) Analysis & Trends

Polaryx Therapeutics (PLYX) has reported Prepaid Assets for 3 consecutive years, with $389000.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Prepaid Assets changed N/A year-over-year to $389000.0; the TTM figure through Mar 2026 stood at $389000.0 (changed N/A YoY), while the FY2025 annual figure was $27000.0, down 92.89% from the prior year.
Prepaid Assets rose to $389000.0 in Q1 2026 per PLYX's latest filing, from $27000.0 in the prior quarter.
Across five years, Prepaid Assets topped out at $389000.0 in Q1 2026 and bottomed at $27000.0 in Q4 2025.
Historically, Prepaid Assets has averaged $265333.3 across 3 years, with a median of $380000.0 in 2024.
On a YoY basis, Prepaid Assets climbed as much as 92.89% in 2025 and fell as far as 92.89% in 2025.
Polaryx Therapeutics' Prepaid Assets stood at $380000.0 in 2024, then slumped by 92.89% to $27000.0 in 2025, then jumped by 1340.74% to $389000.0 in 2026.
Business Quant data shows PLYX's Prepaid Assets at $389000.0 in Q1 2026, $27000.0 in Q4 2025, and $380000.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Polaryx Therapeutics	99.45 Mn	87.91 Mn	-

Download Data